Multimodal Cardiovascular and Hepatic Population Imaging

Condition(s) studied

Investigational drug(s) / intervention(s)

Imaging examinations: * Cardiovascular and diaphragm MRI * Hepatic and kidney MRI * Hepatic ultrasound * Echocardiography

Paramedical examinations: * Urinary pregnancy test for women of childbearing age. * Blood sample for cardiometabolism profiling * Blood samples for biobanking (according to the information and consent form) * Impedancemetry * AGE reader: combined non-invasive measurement of aging and accumulation of glycated proteins in the subcutaneous tissue will be performed with a CE-marked device. * ECG

Medical examination: * Review of risk factors * Review of previous history * Recording of current medication (dci, dose, start date) * Recording of medication in the last 6 months and discontinued since (dci, dose, start date)

Echocardiography: Echocardiography including: 12-lead digital ECG

Study summary

Medical imaging is increasingly important for understanding diseases, detecting them early, and personalizing treatments. New imaging techniques, which can measure processes in the body without surgery, are opening the door to a more precise approach to medicine. Instead of relying on general probabilities, this technology allows us to analyze specific factors in a person's health, leading to better predictions and targeted treatments. One key challenge in medicine today is reducing "residual individual risk"-the remaining health risks that current treatments don't fully address. This involves understanding how factors like age, sex, genetics, and environment affect our health, particularly when it comes to conditions like heart and liver disease. By using imaging to distinguish between normal aging and disease, we can better assess individual health risks.

The current project will create a large collection of medical images linked with health data from a broad population across France. Using advanced, non-invasive techniques such as MRI and ultrasound, researchers will analyze the heart, blood vessels, and liver in detail, considering factors like gender and health risk profiles. This will help improve our understanding of these diseases, which are often silent and not well understood, providing direct benefits to the participants. Ultimately, the goal is to optimize imaging technologies for large-scale studies, which will help enhance early detection and prevention for everyone.

Eligibility

Primary outcome measure(s)

• Establishement of reference nomograms accounting for age in heart — During 36 months of analysis (after 60 months of inclusion)
  Ultrasound and MRI images analysis of qualitative and quantitative morphology, function, quantitative tissue characterization of the heart
• Establishement of reference nomograms accounting for sex in heart — During 36 months of analysis (after 60 months of inclusion)
  Ultrasound and MRI images analysis of qualitative and quantitative morphology, function, quantitative tissue characterization of the heart
• Establishement of reference nomograms accounting for age in liver — During 36 months of analysis (after 60 months of inclusion)
  Ultrasound and MRI images analysis of quantitative steatosis, fibrosis
• Establishement of reference nomograms accounting for sex in liver — During 36 months of analysis (after 60 months of inclusion)
  Ultrasound and MRI images analysis of quantitative steatosis, fibrosis
• Establishement of reference nomograms accounting for age in adipose tissue — During 36 months of analysis (after 60 months of inclusion)
  Ultrasound and MRI images analysis of volumes of subcutaneous, visceral and epicardial adipose tissues
• Establishement of reference nomograms accounting for sex in adipose tissue — During 36 months of analysis (after 60 months of inclusion)
  Ultrasound and MRI images analysis of volumes of subcutaneous, visceral and epicardial adipose tissues
• Establishement of reference nomograms accounting for sex in diaphragm — During 36 months of analysis (after 60 months of inclusion)
  Ultrasound and MRI images analysis of diaphragm
• Establishement of reference nomograms accounting for age in diaphragm — During 36 months of analysis (after 60 months of inclusion)
  Ultrasound and MRI images analysis of diaphragm
• Establishement of reference nomograms accounting for sex in kidney — During 36 months of analysis (after 60 months of inclusion)
  Ultrasound and MRI images analysis of kidney

Trial sites (1)

More Institut National de la Santé Et de la Recherche Médicale, France trials in France

Other trials for the same condition